Saspase-flg2 complex, modulating agents, and uses
AssigneeL'oreal
InventorsDominique Bernard, Agnes Thomas-Collignon, Roger Rozot, Benoit Muller
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a compound, suitable for modulating the interaction between first and second partner proteins, or between homologues, mutants, or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, as an active agent for treating and/or preventing aesthetic defects in the skin, and/or in the appendages thereof, linked to an imbalance in the differentiation and/or proliferation of the cells of the epidermis.
Claims32
A process for treating and/or preventing an esthetic defect of the skin and/or its integuments associated with an imbalance in epidermal cell differentiation and/or proliferation, the process comprising:
- administering, to an individual in need thereof, an active agent comprising a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2.
A process for promoting re-epithelialization after a cutaneous scrubbing or exfoliant treatment, the process comprising:
- administering, to an individual in need thereof, an active agent comprising a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2.
A process for preventing and/or treating hair loss and/or promoting hair regrowth, or for preventing bodily hair regrowth, the process comprising:
- administering, to an individual in need thereof, an active agent comprising a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2.
A process for the in vitro or ex vivo screening of compounds that are capable of regulating the proliferation and/or differentiation of epidermal cells, the process comprising:
- modulating the interaction between a first and a second protein of a protein complex comprising said first and said second partner protein interacting with each other, said first and second proteins being SASPase and filaggrin-2, or FLG2, homologs, mutants or fragments of said proteins.
A process for the in vitro or ex vivo screening of a compound that is capable of regulating the proliferation and/or differentiation of epidermal cells by modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, said process comprising:
- a) placing said first and second proteins under conditions suitable for interaction between the first and second proteins;
- b) combining, before or after a), at least one of the first and second proteins with a species, said protein forming with said species an assembly capable of emitting a signal after exposure to an excitatory wavelength, and the implementation of a) and b) leading to the production of a complex by interaction of said first and second partner proteins;
- c) subjecting said complex to said excitatory wavelength, to obtain a first signal S1 characteristic of said complex;
- d) determining quantitatively or qualitatively said signal S1;
- e) placing the complex in contact with a medium assumed to contain a compound to be screened under conditions suitable for interaction between said compound and said complex;
- f) subjecting the medium obtained in e) to said excitatory wavelength, to obtain a second signal S2;
- g) determining quantitatively or qualitatively said signal S2;
- and
- h) comparing the first and second signals S1 and S2 in order to draw a conclusion relating to a possible modulation of the interaction between the first and second proteins by the screened compound.
A pharmaceutical or dermatological composition comprising, in a physiologically acceptable medium, at least an effective amount of a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2.
A cosmetic composition comprising, as active agent, in a physiologically acceptable medium, at least an effective amount of a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, and at least one cosmetically or dermatologically acceptable ingredient selected from the group consisting of cosmetic or dermatological active agents, preserving agents, hydrophilic or lipophilic gellants, nonionic, anionic or cationic surfactants, antioxidants, salts, fragrances, fillers, odor absorbers, dyestuffs, film-forming polymers, semicrystalline polymers, gums and volatile or nonvolatile oils, and mixtures thereof.
An article a cosmetic, pharmaceutical or dermatological composition comprising a compound that is capable of modulating the interaction between a first and a second partner protein, homologs, mutants or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2.
(canceled)
A protein complex comprising a first and a second partner protein that interact with each other, said first and second proteins being SASPase and filaggrin-2, or FLG2, homologs, mutants or fragments of said proteins.
Dependencies are inferred from the claim text.